The effect of maintenance therapy on Crohn’s disease clinical outcomes
https://doi.org/10.22416/1382-4376-2016-6-112-119
Abstract
Aim of investigation. To study the effect of maintenance therapy on clinical outcomes of Crohn’s disease (CD) in patients with inflammatory and complicated forms. Material and methods. Five-year prospective study of 210 patients with CD receiving maintenance therapy was carried out. Treatment response was estimated in real-life conditions according to the guidelines of European Crohn's and Colitis Organisation (ECCO). Treatment response and failure at different types of pharmaceutical treatment were estimated. Results. At mesalazine maintenance therapy in patients with inflammatory forms of CD there was no statistically significant demand in treatment enhancement for medium-term perspective (р=0,0088, OR=0,46, 95% CI=0,26-0,80). «The steroid-sparing effect» of immunosuppressors was observed generally in all patients with inflammatory form of disease, which provided reduction of steroid dependency rate by 17%. Repeated prescription of systemic steroids led to development ofsteroid-dependency in complicated forms more frequently (p=0,0083, OR=10,1, 95% CI=1,9-52,5). The long-term outcomes related to biological maintenance therapy demonstrate more frequent mucosal healing at inflammatory (p=0,0423, OR=3,3, 95%CI=1,2-9,4), though not for complicated forms of disease. Conclusions. Mesalazine maintenance therapy is possible only at patients with the inflammatory form of CD without systemic activity under close follow-up by physician. In order to avoid disease progression it is necessary to avoid repeated application of systemic steroids at uncomplicated forms of disease. In complicated cases the combination of systemic steroids and immunosuppressants is ineffective. Biological therapy should be considered as disease-modifying treatment in patients with inflammatory forms of CD. The decision on pharmaceutical treatment of patients with complications should be made by gastroenterologists in consort with surgeons-coloproctologists.
About the Authors
O. B. Schukina
State educational government-financed institution of higher professional education «Mechnikov North-Western State Medical University»
Russian Federation
Russian Federation
E. A. Kondrashina
Saint-Petersburg University
Russian Federation
Russian Federation
A. M. Kharitidis
City clinical hospital No. 31
Russian Federation
Russian Federation
Ye. G. Vepreva
City clinical hospital No. 31
Russian Federation
Russian Federation
A. G. Kharitonov
City clinical hospital No. 31
Russian Federation
Russian Federation
A. Yu. Baranovsky
Saint-Petersburg University
Russian Federation
Russian Federation
References
1. Ramadas A. V., Gunesh S., Thomas G. A., Williams G. T., Hawthorne A. B. Natural history of Crohn’s disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010; 59(9):1200-6.
2. Reinisch W., Wang Y., Oddens B. J. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn’s disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther 2012; 35:568-76.
3. Rutgeerts P., van Assche G., Sandborn W. J. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology 2012; 142:1102-11.
4. Moran G. W., Dubeau M. F., Kaplan G. G., Yang H., Seow C. H., Fedorak R. N., Dieleman L. A., Barkema H. W., Ghosh S., Panaccione R. Alberta inflammatory bowel disease consortium. Phenotypic features of Crohn’s disease associated with failure of medical treatment. Clin Gastroenterol Hepatol 2014; 12(3):434-42.
5. Peyrin-Biroulet L., Oussalah A., Williet N., Pillot C., Bresler L., Bigard M. A. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn’s disease. Gut 2011; 60(7):9306.
6. Cosnes J., Nion-Larmurier I., Beaugerie L., Afchain P., Tiret E., Gendre J. P. Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery. Gut 2005; 54(2):237-41.
7. Thia K. T., Sandborn W. J., Harmsen W. S. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology 2010; 139:1147-55.
8. Silverberg M. S., Satsangi J., Ahmad T. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol Hepatol 2005 Sep; 19 (Suppl. SA): 5-36.
9. Dignass A., Van Assche G., Lindsay J. O., Lémann M., Söderholm J., Colombel J. F., Danese S., D’Hoore A., Gassull M., Gomollón F., Hommes D. W., Michetti P., O’Morain C., Oresland T., Windsor A., Stange E. F., Travis S. P. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohns Colitis 2010; 4(1):28-62.
10. Su C., Lichtenstein G. R., Krok K., Brensinger C. M., Lewis J. D. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn’s disease. Gastroenterology 2004; 126(5):1257-69.
11. Российская гастроэнтерологическая ассоциация, Ассоциация колопроктологов России. Клинические рекомендации по диагностике и лечению взрослых пациентов с болезнью Крона. 2013. URL: http:// www., gastro.ru/userfiles/Recom_BK.pdf.
12. Frøslie K. F., Jahnsen J., Moum B. A., Vatn M. H.; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133(2):412-22.
13. Bokemeyer B., Katalinic A., Klugmann T., Franke G., Weismuller J., Ceplis-Kastner S., Reimers B., Kruis W. Predictive factors for a mild course of Crohn’s disease. J Crohn’s Colitis 2009; 3:82.
14. Hanauer S. B., Strömberg U. Oral Pentasa in the treatment of active Crohn’s disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004; 2(5):379-88.
15. Travis S. P., Stange E. F., Lémann M., Oresland T., Chowers Y., Forbes A., d’Haens G., Kitis G., Cortot A., Prantera C., Marteau P., Colombel J. F., Gionchetti P., Bouhnik Y., Tiret E., Kroesen J., Starlinger M., Mortensen N. J. European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut 2006; 55 (Suppl. 1):i16-35.
16. Olaison G., Sjödahl R., Tagesson C. Glucocorticoid treatment in ileal Crohn’s disease: relief of symptoms but not of endoscopically viewed inflammation. Gut 1990; 31(3):325-8.
17. Ho G. T., Chiam P., Drummond H., Loane J., Arnott I. D., Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006; 24(2):319-30.
18. Hindorf U., Lindqvist M., Hildebrand H., Fagerberg U., Almer S. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24(2):331-42.
19. Lemann, M., Cuillerier, E., Bouhnik, Y., et al. Azathioprine (AZA) for prevention of Crohn’s recurrence after ileal or colonic resection. Gastroenterology 1996; 110:948.
20. De Cruz P., Kamm M. A., Hamilton A. L., et al. Efficacy of thiopurines and adalimumab in preventing Crohn’s disease recurrence in high-risk patients - a POCER study analysis. Aliment Pharmacol Ther 2015; 42(7):867-79.
21. Sandborn W. J., Hanauer S., van Assche G., Panés J., Wilson S., Petersson J., Panaccione R. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis 2014; 8(9):927-35.
22. Hanauer S. B., Feagan B. G., Lichtenstein G. R., et al. Maintenance infliximab for Crohn‘s disease: the ACCENT I randomised trial. Lancet 2002; 359:1541-9.
23. Vermeire S., Louis E., Carbonez A., van Assche G., Noman M., Belaiche J., de Vos M., van Gossum A., Pescatore P., Fiasse R., Pelckmans P., Reynaert H., D’Haens G., Rutgeerts P. Demographic and clinical parameters influencing the short-term outcome of antitumor necrosis factor (inf liximab) treatment in Crohn’s disease. Am J Gastroenterol 2002; 97(9):2357-63.
24. Shental O., Tulchinsky H., Greenberg R., et al. Positive histological inflammatory margins are associated with increased risk for intra-abdominal septic complications in patients undergoing ileocolic resection for Crohn’s disease. Dis Colon Rectum 2012; 55:1125-30.
Review
For citations:
Schukina O.B., Kondrashina E.A., Kharitidis A.M., Vepreva Ye.G., Kharitonov A.G., Baranovsky A.Yu. The effect of maintenance therapy on Crohn’s disease clinical outcomes. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(6):112-119. (In Russ.) https://doi.org/10.22416/1382-4376-2016-6-112-119
Views:
1181
Email this article 
